No information is available on the clinical use of efgartigimod alfa during breastfeeding. Because efgartigimod alfa is a large protein molecule with a molecular weight of 54,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, efgartigimod alfa should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1]
关于在母乳喂养期间使用阿伐吉莫德的临床信息尚无可用数据。由于阿伐吉莫德是一种分子量为54,000道尔顿的大蛋白质分子，乳汁中的含量可能非常低。它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收量可能极小。在获得更多数据之前，母乳喂养期间应谨慎使用阿伐吉莫德，尤其是在哺育新生儿或早产儿期间。产后至少等待2周再恢复治疗可能会使药物向婴儿的转移降至最低。[1]
